Q-omics provides the consensus-scored GSDMB profile across patient tissues and cancer cell-line models. GSDMB expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, GSDMB is differentially expressed in 15, with the highest sampling consensus in THCA. Additionally, GSDMB RNA expression shows 18,481 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BLCA, THCA, and UVM as cancer lineages where GSDMB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GSDMB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GSDMB survival associations across molecular data types. GSDMB RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GSDMB RNA expression–survival associations across cancer types. High GSDMB expression shows unfavorable associations in KIRC, ACC and KICH, but favorable associations in BLCA, SKCM and UCS. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for GSDMB RNA expression.
This table summarizes GSDMB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for GSDMB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GSDMB shows higher tumor expression in THCA, KIRC, HNSC, LUAD, STAD and LIHC. The THCA box plot shows higher GSDMB RNA expression in tumor versus normal tissue (log2 FC = +0.776, t-test p < 0.001).
This table shows molecular features associated with GSDMB in patient tissues and cancer cell lines. In patient samples, GSDMB shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, GSDMB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BLOOD_Leukemia.
